Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
eNq1mE1z2jAQhu/8Co8PvWHjEBJobTItTVpmkiklYdrphRH2EkSF5OiDj/76ypg0pCM3jUBHW/a7K+3q0TuKL9YL4i2BC8xo4kdBw/eApizD9D7xR3dX9bZ/0a3Fc7REe5+dB40gOvG9lCAhEr8YDSaAqAi+31x/BP0/cL9b82I2mUMqn32nJCbBZyRmNygvvvHiJcOZtwA5Y1ni50pu33qxkFxn0V0x/lPkKIU43L3ZH52PT/ffx2Eh9h+qSgC/RvTeKArUSjNVnAOVPSThnvFNRb5NK20shiCY4ikMkJwNOFviDDJjiCkiAqyCTFfZLfAlAVkEMYqH83QhrMTRHK2H8NA3J/1ej/bkWtYb9ej8vNVunrWiRuukYxWK7y2VuQp6EmE6jprN03ajHQINHxQSm0Wd5JbVGTAuEXFUFyx6z1vLURwODy/WP8MiJ2gTzIX1UiGO9DBwDQB3EylmcMc1kohes7/0qSIkfGXWox0wHGVc8KjHFJUV3Lga2i5Ej1EJ6+qK2qFOrne9iEEcT/YXo2bMD9SE4NQWaho7CoQcDfvVTDsuDj4gASPujgffMM3YShyfM/t1dZR9vkWlUTTnWTQ+6bTPolbLehv90E1UccpcKs5yCDWBsDgELH06ZYciRfelWeqxK4/YkFu3w1JEoMLv1C35ojvx0Z4563V3+6gcMIp+uryzbZCvCvjmdvtolMZZ8qe0dvB1QXTdji8lXm7cJB83G612p3n6Bi3yd49GOrE0zaWoE8+suJkyMylz8TYMV6tVMEOiLpBez2DK/3UOXBgnf4wF0NB9qqc7Y+/EBpS2qASuo9Qn5Un6ukLabt2XjMKh5nf3/85kG2NIruCAWpSUd8bi/uXx8f7kfJ2lPXgGGXdhti4VScyoK++kJkbFww4UXVd6xTUgvkynuOKipbIv47C85OnW4rC44OnWfgMq2ANH
4tG5Yt9UxxnuhMFB
